News & Events

26 September 2023

3rd A-TANGO GA Meeting - remote

A-TANGO's 3rd General Assembly (GA) Meeting takes place via Zoom on Tuesday, 26 September 2023. Check your email for the agenda and the Zoom-Link! We are looking forward to hearing about everyone's progress and the details of the planned start of the clinical G-TAK study. Besides updates on all work packages (WPs), we also have to discuss current issues and decide on mitigation measures to move the project forward. The early-career scientists (ECS) programme will include a Masterclass by Isabelle Durand-Zaleski (APHP) on "Health Economics in Liver Disease" and first results of the ancillary studies.

28 June 2023

Successful 5th Steering Committee Meeting

Two years and four months into the project, A-TANGO has overcome tremendous challenges and is coming closer to enrolling the first late-stage cirrhosis patient into the clinical "G-TAK" study in autumn. At today's 5th Steering Committee Meeting (28 June), we realized how far we've come and that we may just get to tackle that very serious disease, called acute-on-chronic liver failure (ACLF). A big thank you to the whole team for all your hard work! Big efforts often require tough decisions, but what counts most is that the entire consortium is committed to bringing this novel combinatorial therapy to those who desperately need it - the patients.

22 June 2023

Symposium on late-stage cirrhosis treatment at EASL Congress on Saturday

With 9000 participants from 120 countries & 2500 submitted abstracts, "EASL Congress 2023" is already a success again. Don't forget to attend this symposium on "Novelties in the therapeutic landscape for acute decompensation of cirrhosis" on Saturday, 24 June 2023 from 8:30 - 09:45 CEST (room: Strauss 1). A-TANGO coordinator Prof. Rajiv Jalan from EF CLIF, Dr. Minneke Coenraad from Leiden University Medical Center (LUMC), and Dr. Cornelius Engelmann from the Charité will discuss their insights, including A-TANGO's G-TAK study.


More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more


  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more


Prof. Dr. Rajiv Jalan (EF CLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona


Dr. med. Cornelius Engelmann (Charité)
Augustenburger Platz 1
13353 Berlin


concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck